Is United Therapeutics Stock a Good Investment?
United Therapeutics Investment Advice | UTHR |
- Examine United Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research United Therapeutics' leadership team and their track record. Good management can help United Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact United Therapeutics' business and its evolving consumer preferences.
- Compare United Therapeutics' performance and market position to its competitors. Analyze how United Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if United Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about United Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in United Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if United Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine United Therapeutics Stock
Researching United Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company outstanding shares are owned by institutional investors. The book value of United Therapeutics was at this time reported as 143.74. The company has Price/Earnings To Growth (PEG) ratio of 1.43. United Therapeutics recorded earning per share (EPS) of 24.63. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 23rd of September 2009.
To determine if United Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding United Therapeutics' research are outlined below:
| United Therapeutics generated a negative expected return over the last 90 days | |
| United Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: New York City Surgeon Presented with the Excellence in Kidney Transplantation Award |
United Therapeutics Quarterly Cost Of Revenue |
|
United Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in United Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to United Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact United Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises United Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2003-11-06 | 2003-09-30 | -0.04 | -0.03 | 0.01 | 25 | ||
2005-05-03 | 2005-03-31 | 0.14 | 0.16 | 0.02 | 14 | ||
2003-05-06 | 2003-03-31 | -0.09 | -0.07 | 0.02 | 22 | ||
2003-02-25 | 2002-12-31 | -0.08 | -0.06 | 0.02 | 25 | ||
2002-11-08 | 2002-09-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2010-04-29 | 2010-03-31 | 0.29 | 0.32 | 0.03 | 10 | ||
2008-05-01 | 2008-03-31 | 0.27 | 0.24 | -0.03 | 11 | ||
2004-05-06 | 2004-03-31 | -0.01 | -0.04 | -0.03 | 300 |
Know United Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as United Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading United Therapeutics backward and forwards among themselves. United Therapeutics' institutional investor refers to the entity that pools money to purchase United Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alliancebernstein L.p. | 2024-12-31 | 709 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 620.6 K | Pacer Advisors, Inc. | 2024-12-31 | 597.6 K | Arrowstreet Capital Limited Partnership | 2024-12-31 | 542.4 K | Fuller & Thaler Asset Management Inc | 2024-12-31 | 532.9 K | Northern Trust Corp | 2024-12-31 | 488.9 K | Hhg Plc | 2024-12-31 | 469 K | Norges Bank | 2024-12-31 | 430.1 K | Genworth Financial Wealth Mgmt Inc | 2024-12-31 | 429.2 K | Wealthfront Advisers Llc | 2024-12-31 | 18.3 M | Blackrock Inc | 2024-12-31 | 5.4 M |
United Therapeutics' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 14.37 B.Market Cap |
|
United Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.16 | 0.17 | |
| Return On Capital Employed | 0.21 | 0.22 | |
| Return On Assets | 0.16 | 0.17 | |
| Return On Equity | 0.19 | 0.19 |
Determining United Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if United Therapeutics is a good buy. For example, gross profit margin measures United Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of United Therapeutics' profitability and make more informed investment decisions.
United Therapeutics' Earnings Breakdown by Geography
Evaluate United Therapeutics' management efficiency
United Therapeutics has return on total asset (ROA) of 0.1244 % which means that it generated a profit of $0.1244 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1923 %, meaning that it created $0.1923 on every $100 dollars invested by stockholders. United Therapeutics' management efficiency ratios could be used to measure how well United Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/25/2025, Return On Tangible Assets is likely to grow to 0.17. Also, Return On Capital Employed is likely to grow to 0.22. At this time, United Therapeutics' Return On Tangible Assets are relatively stable compared to the past year. As of 03/25/2025, Return On Assets is likely to grow to 0.17, while Other Assets are likely to drop slightly above 284.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 142.57 | 149.69 | |
| Tangible Book Value Per Share | 140.09 | 147.10 | |
| Enterprise Value Over EBITDA | 8.80 | 10.80 | |
| Price Book Value Ratio | 2.47 | 4.07 | |
| Enterprise Value Multiple | 8.80 | 10.80 | |
| Price Fair Value | 2.47 | 4.07 | |
| Enterprise Value | 13.1 B | 13.8 B |
Examining the leadership quality of United Therapeutics offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Beta 0.639 |
Basic technical analysis of United Stock
As of the 25th of March, United Therapeutics has the Risk Adjusted Performance of (0.07), variance of 5.45, and Coefficient Of Variation of (1,142). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of United Therapeutics, as well as the relationship between them. Please validate United Therapeutics variance and skewness to decide if United Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 319.86 per share. Given that United Therapeutics has information ratio of (0.08), we advise you to double-check United Therapeutics's current market performance to make sure the company can sustain itself at a future point.United Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific United Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on United Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases United Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
United Therapeutics' Outstanding Corporate Bonds
United Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. United Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most United bonds can be classified according to their maturity, which is the date when United Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| UNITED TECHNOLOGIES P Corp BondUS913017CR85 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CP20 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CW70 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CY37 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CX53 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017DD80 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017BP39 | View |
Understand United Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing United Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.40) | |||
| Mean Deviation | 1.5 | |||
| Coefficient Of Variation | (1,142) | |||
| Standard Deviation | 2.33 | |||
| Variance | 5.45 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.12) | |||
| Treynor Ratio | (0.41) | |||
| Maximum Drawdown | 15.73 | |||
| Value At Risk | (4.23) | |||
| Potential Upside | 2.52 | |||
| Skewness | (1.56) | |||
| Kurtosis | 6.37 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.40) | |||
| Mean Deviation | 1.5 | |||
| Coefficient Of Variation | (1,142) | |||
| Standard Deviation | 2.33 | |||
| Variance | 5.45 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.12) | |||
| Treynor Ratio | (0.41) | |||
| Maximum Drawdown | 15.73 | |||
| Value At Risk | (4.23) | |||
| Potential Upside | 2.52 | |||
| Skewness | (1.56) | |||
| Kurtosis | 6.37 |
Consider United Therapeutics' intraday indicators
United Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of United Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 8785.61 | |||
| Daily Balance Of Power | 0.9172 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 316.93 | |||
| Day Typical Price | 317.9 | |||
| Price Action Indicator | 6.37 | |||
| Period Momentum Indicator | 6.87 |
United Therapeutics Corporate Filings
F4 | 20th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 26th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify | |
| 5th of February 2025 Other Reports | ViewVerify |
United Stock media impact
Far too much social signal, news, headlines, and media speculation about United Therapeutics that are available to investors today. That information is available publicly through United media outlets and privately through word of mouth or via United internal channels. However, regardless of the origin, that massive amount of United data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of United Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of United Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to United Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive United Therapeutics alpha.
United Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards United Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
United Therapeutics Historical Investor Sentiment
Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
United Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for United Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average United Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on United Therapeutics.
United Therapeutics Maximum Pain Price Across June 20th 2025 Option Contracts
United Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of United Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of United Therapeutics' options.
United Therapeutics Corporate Management
| Holly Hobson | Associate Resources | Profile | |
| JD MBA | Chairman Founder | Profile | |
| Gil Golden | Senior Officer | Profile | |
| Dewey CFA | Head Relations | Profile | |
| Kevin Gray | Senior Logistics | Profile |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.